What Happens If You Miss a Dose of Depo-Estradiol

Missing a Dose of Depo‑Estradiol

Short answer: If you miss one Depo‑Estradiol injection by a few days, the depot may continue releasing hormone — however, a missed or delayed dose may allow return of menopausal symptoms, may cause breakthrough bleeding, or may alter hormone levels. According to FDA-approved prescribing information for the commercial Depo-Estradiol product, contact your prescriber as soon as possible if a dose is missed. If the delay is longer (more than 1–2 weeks) or you notice return of hot flashes, bleeding, or other symptoms, contact your prescriber because you may need the injection now or a short-term bridge and specific advice about progestin timing.

Detailed explanation: Per FDA-approved prescribing information for the commercial Depo-Estradiol product, depot (long‑acting) estradiol is designed to release hormone over weeks, so a single short delay may not result in immediate symptoms. What to do depends on how late you are, whether you have a uterus, and whether you have symptoms or risk factors (blood clots, stroke, active cancer). Per FDA-approved prescribing information for the commercial Depo-Estradiol product, guidance includes:

• If less than about 7 days late: per FDA-approved prescribing information for the commercial Depo-Estradiol product, the injection should be obtained as soon as possible; no extra measures are usually needed per your prescriber's guidance.
• If ~1–2 weeks late: per FDA-approved prescribing information for the commercial Depo-Estradiol product, if a dose is missed, obtain the injection right away and contact your clinician — they may accept that dose or may recommend a short course of supplemental therapy until the next scheduled visit.
• If more than 2–4 weeks late or you have returned symptoms: you may need immediate replacement; contact your prescriber to discuss whether your current regimen remains appropriate. Breakthrough bleeding may occur if you have a uterus.
• Do not inject extra doses unless directed by your prescriber: per FDA-approved prescribing information for the commercial Depo-Estradiol product, do not administer two full depot injections at once without explicit prescriber instruction.
• Warning signs described in FDA labeling: per FDA-approved prescribing information for the commercial Depo-Estradiol product, the FDA labeling describes new chest pain, sudden shortness of breath, leg swelling, sudden severe headache, or visual changes as serious events associated with estrogen-containing products, including cardiovascular events, deep vein thrombosis (DVT), pulmonary embolism (PE), endometrial cancer, breast cancer, and probable dementia in women 65+; patients who experience any of these symptoms should contact their prescriber promptly. Whether any individual symptom warrants intervention depends on personal health factors that a clinician must assess, and published guidance from NAMS or ACOG informs how prescribers evaluate them.
• Long gaps (months): repeated missed doses may reduce bone protection and may reduce symptom control; restarting may require a review of risks and benefits and sometimes a different plan.

Contact your prescriber if doses are missed repeatedly or if symptoms change — they may advise the safest option and arrange the injection. This helps protect long‑term health while ensuring your regimen remains appropriate for your needs.